FilingReader Intelligence
Essex Bio-Technology's wet AMD drug gets China regulatory acceptance
August 13, 2025 at 12:10 PM UTC•By FilingReader AI
Essex Bio-Technology Limited announced China's CDE has accepted its application for HLX04-O, an eye injection for wet age-related macular degeneration.
The drug, co-developed with Shanghai Henlius Biotech, met its primary endpoint in phase 3 trials in April 2025. China's wet-AMD drug market was worth approximately 4.9bn yuan in 2024.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:1061•Hong Kong Exchange
News Alerts
Get instant email alerts when Essex Bio-Technology publishes news
Free account required • Unsubscribe anytime